[1]
|
Ferlay, J., Colombet, M., Soerjomataram, I., et al. (2021) Cancer Statistics for the Year 2020: An Overview. Interna-tional Journal of Cancer, 149, 778-789. https://doi.org/10.1002/ijc.33588
|
[2]
|
Kessous, R., Laskov, I., Abitbol, J., et al. (2017) Clinical Outcome of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Gynecologic Oncology, 144, 474-479. https://doi.org/10.1016/j.ygyno.2016.12.017
|
[3]
|
Fagotti, A., Ferrandina, G., Vizzielli, G., et al. (2016) Phase III Randomised Clinical Trial Comparing Primary Surgery versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer with High Tumour Load (SCORPION Trial): Final Analysis of Peri-Operative Outcome. European Journal of Cancer, 59, 22-33.
https://doi.org/10.1016/j.ejca.2016.01.017
|
[4]
|
Kehoe, S., Hook, J., Nankivell, M., et al. (2015) Primary Chemo-therapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Ran-domised, Controlled, Non-Inferiority Trial. The Lancet, 386, 249-257. https://doi.org/10.1016/S0140-6736(14)62223-6
|
[5]
|
王登凤, 张国楠, 彭春蓉, 等. 晚期卵巢上皮性癌患者NACT+IDS治疗模式的预后获益及影响因素分析[J]. 中华妇产科杂志, 2021, 56(6): 385-392.
|
[6]
|
Melamed, A., Hinchcliff, E.M., Clemmer, J.T., et al. (2016) Trends in the Use of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer in the United States. Gynecologic Oncology, 143, 236-240.
https://doi.org/10.1016/j.ygyno.2016.09.002
|
[7]
|
张静柳, 黄俊, 吴歆华. CT联合CA125检测在卵巢癌诊断中的应用价值[J]. 实用癌症杂志, 2015, 30(9): 1290- 1292.
|
[8]
|
Phillips, A., Singh, K., Pounds, R., et al. (2017) Pre-dictive Value of the Age-Adjusted Charlston Co-Morbidity Index on Peri-Operative Complications, Adjuvant Chemo-therapy Usage and Survival in Patients Undergoing Debulking Surgery after Neo-Adjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer. Journal of Obstetrics and Gynaecology, 37, 1070-1075. https://doi.org/10.1080/01443615.2017.1324413
|
[9]
|
Suidan, R.S., Ramirez, P.T., Sarasohn, D.M., et al. (2017) A Multicenter Assessment of the Ability of Preoperative Computed Tomography Scan and CA-125 to Predict Gross Residual Disease at Primary Debulking for Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 145, 27-31. https://doi.org/10.1016/j.ygyno.2017.02.020
|
[10]
|
徐丽萍, 毛竹青, 陈爱平, 等. CT联合血清CA125水平评估卵巢癌行初次理想肿瘤细胞减灭术的临床价值[J]. 现代生物医学进展, 2018, 18(3): 537-540.
|
[11]
|
Fagotti, A., Ferrandina, G., Fanfani, F., et al. (2006) A Laparoscopy-Based Score to Predict Surgical Outcome in Patients with Advanced Ovarian Carcinoma: A Pilot Study. Annals of Surgical Oncology, 13, 1156-1161.
https://doi.org/10.1245/ASO.2006.08.021
|
[12]
|
Saner, F.A.M., Ruggeri, G., Siegenthaler, F., Wampfler, J., Imboden, S. and Mueller, M.D. (2023) Change of Fagotti Score Is Associated with Outcome after Neoadjuvant Chem-otherapy for Ovarian Cancer. International Journal of Gynecological Cancer, 33, 1595-1601. https://doi.org/10.1136/ijgc-2023-004540
|
[13]
|
张盛苗, 夏宝国, 楚蔚昕, 栾少红, 王丽, 聂小倩, 陈龙. 腹腔镜在晚期上皮性卵巢癌诊治中的价值[J]. 中国实用妇科与产科杂志, 2018, 34(1): 114-118.
|
[14]
|
郭融, 蔡钰峰, 王茂淮, 张慧娟. 血清学CA724、CA125检测联合ROMA值在卵巢癌诊断中的价值[J]. 国际检验医学杂志, 2020, 41(2): 168-171+175.
|
[15]
|
Machida, H., Tokunaga, H., Matsuo, K., et al. (2020) Survival Outcome and Perioperative Complication Related to Neoadjuvant Chemotherapy with Carboplatin and Paclitaxel for Advanced Ovarian Cancer: A Systematic Review and Meta-Analysis. European Journal of Surgical Oncology, 46, 868-875. https://doi.org/10.1016/j.ejso.2019.11.520
|
[16]
|
Mahdi, H., Maurer, K.A., Nutter, B., et al. (2015) The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients with Advanced-Stage Cancer of Mullerian Origin Treated with Neoadjuvant Chemotherapy. International Journal of Gyne-cological Cancer, 25, 823-829.
https://doi.org/10.1097/IGC.0000000000000434
|
[17]
|
Pelissier, A., Bonneau, C., Chéreau, E., et al. (2014) CA125 Kinetic Parameters Predict Optimal Cytoreduction in Patients with Advanced Epithelial Ovarian Cancer Treated with Neoadjuvant Chemotherapy. Gynecologic Oncology, 135, 542-546. https://doi.org/10.1016/j.ygyno.2014.09.005
|
[18]
|
李胜霞, 朱晨辰, 张安娜, 等. CA125动力学变化预测新辅助化疗晚期卵巢癌患者满意减瘤临床分析[J]. 现代妇产科进展, 2022, 31(10): 745-750.
|
[19]
|
刘超敏, 王涛. 卵巢癌的生物标志物CA125和HE4研究进展[J]. 甘肃医药, 2019, 38(5): 395-397.
|
[20]
|
Baransi, S., Michaan, N., Gortzak-Uzan, L., et al. (2020) The Accuracy of Ascites Cytology in Diagnosis of Advanced Ovarian Cancer in Post-menopausal Women Prior to Neoadjuvant Chemotherapy. Menopause (New York, N.Y.), 27, 771-775. https://doi.org/10.1097/GME.0000000000001534
|
[21]
|
Wright, A.A., Bohlke, K., Armstrong, D.K., et al. (2016) Neoadjuvant Chemo-Therapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 34, 3460-3473. https://doi.org/10.1200/JCO.2016.68.6907
|
[22]
|
Narasimhulu, D.M., Kumar, A., Weaver, A.L., et al. (2020) Less Guessing, More Evidence in Identifying Patients Least Fit for Cytoreductive Surgery in Advanced Ovarian Cancer: A Triage Algorithm to Individualize Surgical Management. Gynecologic Oncology, 157, 572-577. https://doi.org/10.1016/j.ygyno.2020.03.024
|
[23]
|
Narasimhulu, D.M., Kumar, A., Weaver, A.L., et al. (2019) Using an Evidence-Based Triage Algorithm to Reduce 90-Day Mortality after Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 155, 58-62. https://doi.org/10.1016/j.ygyno.2019.08.004
|
[24]
|
Mavaddat, N., Peock, S., Frost, D., et al. (2013) Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results from Prospective Analysis of EMBRACE. JNCI: Journal of the National Cancer Institute, 105, 812-822.
https://doi.org/10.1093/jnci/djt095
|
[25]
|
Gorodnova, T., Sokolenko, A., Ni, V., et al. (2019) BRCA1-Associated and Sporadic Ovarian Carcinomas: Outcomes of Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy. In-ternational Journal of Gynecological Cancer, 29, 779-786. https://doi.org/10.1136/ijgc-2018-000175
|
[26]
|
Rauh-Hain, J.A., Nitschmann, C.C., Worley, M.J., et al. (2013) Platinum Resistance after Neoadjuvant Chemotherapy Compared to Primary Surgery in Patients with Advanced Epithelial Ovarian Carcinoma. Gynecologic Oncology, 129, 63-68. https://doi.org/10.1016/j.ygyno.2013.01.009
|
[27]
|
张杰. BRCA2关键结构域突变与卵巢癌新辅助化疗获得性铂类耐药的相关性研究[D]: [硕士学位论文]. 南宁: 广西医科大学, 2016.
|
[28]
|
Zhang, G.N., Liu, H., Huang, J.M., et al. (2014) TP53 K351N Mutation-Associated Platinum Resistance after Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer. Gynecologic Oncology, 132(3): 752-757.
https://doi.org/10.1016/j.ygyno.2014.01.028
|
[29]
|
张国楠, 朱熠, 黄建鸣. 紫杉醇在上皮性卵巢癌化疗中的双刃剑效应与对策思考[J]. 中国实用妇科与产科杂志, 2017, 33(1): 21-24.
|
[30]
|
成莉, 李琳, 邢辉. 首次肿瘤细胞减灭术与新辅助化疗后间隔性肿瘤细胞减灭术治疗III和IV期卵巢癌患者后其对铂类药物耐药性及生存期的影响[J]. 中国全科医学, 2014, 17(9): 1021-1025.
|
[31]
|
Coleman, R.L., et al. (2017) Bevacizumab and Paclitaxel-Carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-Sensitive Ovarian Cancer (NRG Oncology/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 18, 779-791.
https://doi.org/10.1016/S1470-2045(17)30279-6
|
[32]
|
卢淮武, 林仲秋. 《2018NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南》解读[J]. 中国实用妇科与产科杂志, 2018, 34(5): 526-536.
|
[33]
|
Li, N., Zhu, J., Yin, R., Wang, J., Pan, L., Kong, B., Zheng, H., Liu, J., Wu, X., Wang, L., Huang, Y., Wang, K., Zou, D., Zhao, H., Wang, C., Lu, W., Lin, A., Lou, G., Li, G., Qu, P., Yang, H., Zhang, Y., Cai, H., Pan, Y., Hao, M., Liu, Z., Cui, H., Yang, Y., Yao, S., Zhen, X., Hang, W., Hou, J., Wang, J. and Wu, L. (2023) Treatment with Niraparib Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 9, 1230-1237. https://doi.org/10.1001/jamaoncol.2023.2283
|
[34]
|
Harter, P., Mouret-Reynier, M.A., Pignata, S., Cropet, C., González-Martín, A., Bogner, G., Fujiwara, K., Vergote, I., Colombo, N., Nøttrup, TJ., Floquet, A., El-Balat, A., Scambia, G., Guerra Alia, E.M., Fabbro, M., Schmalfeldt, B., Hardy-Bessard, A.C., Runnebaum, I., Pujade-Lauraine, E. and Ray-Coquard, I. (2022) Efficacy of Maintenance Olaparib plus Bevacizumab According to Clinical Risk in Patients with Newly Diagnosed, Advanced Ovarian Cancer in the Phase III PAOLA-1/ENGOT-Ov25 Trial. Gynecologic Oncology, 164, 254-264.
https://doi.org/10.1016/j.ygyno.2021.12.016
|
[35]
|
Yoneoka, Y., Ishikawa, M., Uehara, T., Shimizu, H., Uno, M., Murakami, T. and Kato T. (2019) Treatment Strategies for Patients with Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: Interval Debulking Surgery or Additional Chemotherapy? Journal of Gynecologic Oncology, 30, e81. https://doi.org/10.3802/jgo.2019.30.e81
|
[36]
|
Yao, S.E., Tripcony, L., Sanday, K., et al. (2020) Survival Outcomes after Delayed Cytoreduction Surgery Following Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 30, 1935-1942. https://doi.org/10.1136/ijgc-2020-001658
|
[37]
|
Stoeckle, E., Bourdarias, L., Guyon, F., et al. (2014) Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery. Annals of Surgical Oncology, 21, 629-636. https://doi.org/10.1245/s10434-013-3278-x
|
[38]
|
Kang, S. and Nam, B.H. (2009) Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 Studies. Annals of Surgical Oncology, 16, 2315-2320.
https://doi.org/10.1245/s10434-009-0558-6
|
[39]
|
Loizzi, V., Cormio, G., Resta, L., et al. (2005) Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Case- Control Study. International Journal of Gynecological Cancer, 15, 217-223.
https://doi.org/10.1136/ijgc-00009577-200503000-00005
|
[40]
|
Perrone, A.M., Coada, C.A., Ravegnini, G., De Leo, A., Damiano, G., De Crescenzo, E., Tesei, M., Di Costanzo, S., Genovesi, L., Rubino, D., Zamagni, C. and De Iaco, P. (2023) Post-Operative Residual Disease and Number of Cycles of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Carcinoma. International Journal of Gynecological Cancer, 33, 1270-1278. https://doi.org/10.1136/ijgc-2022-004249
|
[41]
|
Vergote, I., Tropé, C.G., Amant, F., et al. (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. The New England Journal of Medicine, 363, 943-953. https://doi.org/10.1056/NEJMoa0908806
|
[42]
|
Basaran, D., Boerner, T., Suhner, J., Sassine, D., Liu, Y., Grisham, R.N., Tew, W.P., Gardner, G.J., Zivanovic, O., Sonoda, Y., Long Roche, K., Chi, D.S., Abu-Rustum, N.R., Soff, G.A. and Jewell, E.L. (2021) Risk of Venous Thromboembolism in Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy. Gynecologic Oncology, 163, 36-40.
https://doi.org/10.1016/j.ygyno.2021.07.030
|